NMRA vs OGN · $283.5M cap vs P/E 3.4, rev $6.40B
Neumora Therapeutics, Inc. (NMRA) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company listed on NASDAQ.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
NMRA does not have a complete income-statement cache yet.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
NMRA currently screens at market cap $283.5M. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the NMRA and OGN stock pages for the full models.
Not investment advice.